Immatics N.V. IMTX
$9.18
▲ +3.53% 24H
About
Immatics N.V. is a biotechnology company dedicated to the discovery and development of T-cell redirecting cancer immunotherapies. The company's primary function is to harness the power of the body's immune system to target and eliminate cancer cells, facilitating the development of personalized treatment approaches. Im…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryGermany
Employees678
TickerIMTX
Statistics
Market Cap$1.25B
Revenue (TTM)$48.3M
Net Income-$196.4M
Net Margin-407.0%
EPS$-1.97
P/E26.82
P/S33.20
P/B2.15
EV/EBITDA-3.79
ROE-43.2%
Dividend Yield—
Price$9.18
Data: Twelve Data · Revenue = mcap / P/S